Subconjunctival Injection of Hyaluronic Acid Versus Triamcinolone Acetonide in Thyroid Eye Disease-related Upper Eyelid Retraction: A Pilot Study
Aesthetic Plastic Surgery · 17.11.2026
DOI: 10.1007/s00266-026-06437-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aesthetic Plastic Surgery, online erschienen am 17.11.2026. Verfasst von Fabio Daniel Padilla-Pantoja und 4 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben.
Abstract (Originalsprache)
Purpose
To objectively assess the preliminary effectiveness and safety of subconjunctival injection of hyaluronic acid (HA) and triamcinolone acetonide (TA) in the management of upper eyelid retraction (UER) in patients with thyroid eye disease (TED) through a quantitative image-based approach.
Methods
In this prospective, exploratory pilot study, patients were randomly assigned to receive a single subconjunctival injection of either HA (Restylane Eyelight®, Galderma, Q-med, Sweden) or TA (Trigon Depot®, Bristol-Myers Squibb, Spain). Standardized frontal digital photographs were taken at baseline and during follow-up visits at one, three, and six months. The margin-reflex distance 1 (MRD1) was measured using ImageJ software. Data were analyzed primarily with nonparametric tests (Wilcoxon and Mann–Whitney) and confirmed with repeated-measures ANOVA using the Greenhouse–Geisser correction. Patient satisfaction and adverse events were recorded.
Results
Sixteen eyes from 13 patients (mean age 45.5 ± 8.7 years; 75% female) were included. Eleven eyes (68.8%) received TA and five received HA. Both groups showed a significant reduction in MRD1 over time (Wilcoxon p 0.05). The lowest mean MRD1 (5.20 ± 1.01 mm; 95% CI 4.78–5.91) was observed at three months. Satisfaction rates were high and comparable ( p = 0.252). No serious adverse events occurred; mild transient edema and small depot formation were observed.
Conclusion
This exploratory study represents the first quantitative comparison between subconjunctival HA and TA injections for TED-related UER. Both agents may provide measurable improvement in eyelid position with acceptable safety, and TA achieved outcomes comparable to HA. These findings support their potential role as minimally invasive, non-surgical options for mild to moderate cases and should be confirmed in larger, controlled studies with longer follow-up. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Zitieren
APA
Padilla-Pantoja, F. D., Sanchez-Tocino, H., Bermúdez-Castellanos, I., Marqués-Fernández, V. E., & Galindo-Ferreiro, A. (2026). Subconjunctival Injection of Hyaluronic Acid Versus Triamcinolone Acetonide in Thyroid Eye Disease-related Upper Eyelid Retraction: A Pilot Study. Aesthetic Plastic Surgery. https://doi.org/10.1007/s00266-026-06437-3
Vancouver
Padilla-Pantoja FD, Sanchez-Tocino H, Bermúdez-Castellanos I, Marqués-Fernández VE, Galindo-Ferreiro A. Subconjunctival Injection of Hyaluronic Acid Versus Triamcinolone Acetonide in Thyroid Eye Disease-related Upper Eyelid Retraction: A Pilot Study. Aesthetic Plastic Surgery. 2026. doi:10.1007/s00266-026-06437-3
BibTeX
@article{PadillaPantoja2026,
author = {Padilla-Pantoja, Fabio Daniel and Sanchez-Tocino, Hortensia and Bermúdez-Castellanos, Irene and Marqués-Fernández, Victoria Eugenia and Galindo-Ferreiro, Alicia},
title = {Subconjunctival Injection of Hyaluronic Acid Versus Triamcinolone Acetonide in Thyroid Eye Disease-related Upper Eyelid Retraction: A Pilot Study},
journal = {Aesthetic Plastic Surgery},
year = {2026},
doi = {10.1007/s00266-026-06437-3}
}
EUVIMED